---
title: "ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET | ANIP Stock News"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275895032.md"
description: "ANI Pharmaceuticals, Inc. will release its fourth quarter and full year 2025 financial results on February 27, 2026, at 8:00 a.m. ET. A conference call will be hosted by CEO Nikhil Lalwani and other executives to discuss the results. The live and archived webcast will be available on the Company’s website. ANI Pharmaceuticals focuses on developing innovative therapeutics in various medical fields, including rare diseases, generics, and branded products."
datetime: "2026-02-13T03:50:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275895032.md)
  - [en](https://longbridge.com/en/news/275895032.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275895032.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275895032.md) | [English](https://longbridge.com/en/news/275895032.md)


# ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET | ANIP Stock News

PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to the market open.

Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a conference call to discuss the results as follows:

Date

Friday, February 27, 2026

Time

8:00 a.m. ET

Toll free (U.S.)

800-274-8461

Conference ID

5230834

Webcast (live and replay)

www.anipharmaceuticals.com, under the “Investors” section

  
The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 12 months following the event.

**About ANI**  
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.

**Investor Relations:**  
Courtney Mogerley, Argot Partners  
T: 646-368-8014  
E: ani@argotpartners.com

### 相關股票

- [ANI Pharma (ANIP.US)](https://longbridge.com/zh-HK/quote/ANIP.US.md)

## 相關資訊與研究

- [10:20 ETInnocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest](https://longbridge.com/zh-HK/news/281204522.md)
- [ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of "Buy" from Brokerages](https://longbridge.com/zh-HK/news/266143875.md)
- [AITX Wraps Inaugural Global Sales Conference After ISC West](https://longbridge.com/zh-HK/news/281205719.md)
- [AITX Highlights Record ISC West 2026 Presence, Partnerships](https://longbridge.com/zh-HK/news/281002644.md)
- [Here's How Much You Would Have Made Owning Energy Transfer Stock In The Last 5 Years](https://longbridge.com/zh-HK/news/281083519.md)